| Revenue growth | 39.5% YoY INR; 5.6% QoQ; fifth straight quarter above 5% |
|---|---|
| Margins | EBITDA 16.7%, down 0.2pt QoQ; wage hike absorbed; levers build into Q4 |
| Demand visibility | Healthy pipeline; GenAI deal wins; favourable industry tailwinds |
| Management confidence | Growth and margin expansion to converge in H2 |
Growth
Revenue +39.5% YoY in INR, +27.5% in USD; H1 FY27 revenue INR 21,854M (+39.6%). EBITDA +32% YoY.
Outlook
No numeric guidance. Management expects EBITDA to grow faster than revenue, with PAT margin expanding faster than EBITDA in H2.
Risks
Post US rate-hike yield dip cut PBT margin 90 bps. Wage hike cut EBITDA margin 150 bps QoQ. PAT down 3.4% QoQ.
Investor Presentation filed with BSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹594.70
- Market cap
- ₹14,328 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 35.7×Sector 52.0×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 12.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Management Change
Indegene's Company Secretary and Compliance Officer Srishti Ramesh Kaushik resigned, effective 02-Dec-2026. The resignation cites future career advancement.
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Indegene Q2 FY27 Results: Net Profit ₹112.3 Cr, Up 10.0% YoY
Indegene Ltd reported revenue from operations of ₹1,122 Cr (+39.6% YoY) and net profit of ₹112.3 Cr (+10.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹112.3 Cr · +10.0% YoY
Indegene Merger & Restructuring
Indegene Ltd disclosed that its step-down wholly owned subsidiary, Indegene Portugal Unipessoal LDA, was incorporated on 23 October 2026. The entity has nil turnover and is yet to begin operations.
Indegene Business Update
Indegene received Frost & Sullivan's 2026 Global Enabling Technology Leadership award for AI-powered pharma commercialization. The recognition highlights its domain-led AI platform and workflow transformation capabilities.